ABEO Abeona Therapeutics Inc.

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan

Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
EN
06/10/2020

Underlying

ABEOAbeona Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On August 31, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to seven individuals hired by Abeona, which equity awards relate to, i...

September 2, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces Participation in Upcoming Investor Conf...

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2025: Cantor Global Healthcare Conference 2025: Fireside chat on Thursday, September 4, 2025 at 10:20 a.m. ET and investor meetings.H.C. Wainwright 27th Annual Global Investment Conference: Company presentation on Tuesday, September 9, 2025 at 2:00 p.m. ET and investor meetings. A live webcast of the presentation ...

August 29, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and...

Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates - Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch on track and first ZEVASKYN patient treatment expected in 3Q 2025, momentum building with strong patient interest at qualified treatment centers and referrals, positive insurance coverage established with multiple national and regional payers - - $226M in ...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On July 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to 14 individuals hired by Abeona, which equity awards relate to, in the ...

August 1, 2025 1 EN
 PRESS RELEASE
Free
ABEO Abeona Therapeu...

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center...

ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 - - ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activati...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch